A systematic review and meta-analysis sought to determine the risk of secondary primary cancer for survivors of colorectal cancer.
All articles by Vicki Moore, PhD
Neoadjuvant nivolumab and ipilimumab produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to the lead study author.
Overall, adjuvant chemotherapy does not appear to increase the risk of second cancers for patients with stage III-IV colon cancer.
ACS Cancer Action Network’s Survivor Views panel reveals willingness and concerns of survivors and patients regarding cancer clinical trial participation during the pandemic.
Patient-reported outcomes reports regarding weight loss and dietetic interventions showed dietetic consultations improved OS.
Researchers sought to determine the effects of providing early interdisciplinary care on overall survival, progression-free survival, and adverse events in previously untreated patients with esophagogastric cancer.
Population-based analysis identified trends in incidence and disease-free survival for patients with advanced-stage carcinoma across 3 age groups.
A retrospective study sought to determine the accuracy of the GNRI in predicting postoperative complications and overall survival in elderly patients with colorectal cancer.
Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
The effectiveness of using an educational video and booklet to improve patients’ expectations of cure from palliative chemotherapy was investigated in this study.